Abstract
Objective
There is currently no uniform definition for antimicrobial treatment failure for adults with non-purulent skin and soft tissue infections (SSTIs). The objective of this systematic review was to identify treatment failure definitions and their common components in the literature.
Methods
Five electronic databases were searched from inception to March 2019. Two independent reviewers identified studies involving adults (age ≥ 18 years) with non-purulent SSTIs in which antimicrobial treatment failure was a defined outcome. There were no language restrictions. Only randomized trials or observational studies were included.
Results
After screening 4953 abstracts, 26 studies (N = 6629 patients) met full inclusion criteria. Reported treatment failure ranged from 0 to 29.5%. The most common definition components were hospital admission (78.9%), change in antibiotics (65.4%), and persistent or worsening signs and symptoms of infection (34.6%). Only one study listed specific criteria for persistent or worsening signs and symptoms of infection.
Conclusions
For studies involving non-purulent SSTIs, the outcome of treatment failure is inconsistently defined and reported failure rates are highly variable. This systematic review has highlighted the need for more robust treatment failure definitions for non-purulent SSTIs. Research should focus on the development of a uniform treatment failure definition that should be used in future studies.
Similar content being viewed by others
References
Stevens DL, Eron LL. Cellulitis and soft-tissue infections. Ann Intern Med. 2009;150:ITC11.
Hersh AL, Chambers HF, Maselli JH, Gonzales R. National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Arch Intern Med. 2008;168:1585–91.
Pallin DJ, Egan DJ, Pelletier AJ, Espinola JA, Hooper DC, Camargo CA Jr. Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus. Ann Emerg Med. 2008;51:291–8. https://doi.org/10.1016/j.annemergmed.2007.12.004.
Pallin DJ, Camargo CA Jr, Schuur JD. Skin infections and antibiotic stewardship: analysis of emergency department prescribing practices, 2007–2010. West J Emerg Med. 2014;15:282–9. https://doi.org/10.5811/westjem.2013.8.18040.
Venkatesh AK, Dai Y, Ross JS, Schuur JD, Capp R, Krumholz HM. Variation in US hospital emergency department admission rates by clinical condition. Med Care. 2015;53:237–44. https://doi.org/10.1097/MLR.0000000000000261.
Yadav K, Suh KN, Eagles D, MacIsaac J, Ritchie D, Bernick J, et al. Predictors of oral antibiotic treatment failure for non-purulent skin and soft tissue infections in the emergency department. Acad Emerg Med. 2018;2018:13492.
Talan DA, Salhi BA, Moran GJ, Mower WR, Hsieh YH, Krishnadasan A, et al. Factors associated with decision to hospitalize emergency department patients with skin and soft tissue infection. West J Emerg Med. 2015;16:89–97.
Pollack CV Jr, Amin A, Ford WT Jr, Finley R, Kaye KS, Nguyen HH, et al. Acute bacterial skin and skin structure infections (ABSSSI): practice guidelines for management and care transitions in the emergency department and hospital. J Emerg Med. 2015;48:508–19.
Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59:e10–52. https://doi.org/10.1093/cid/ciu444.
Lymphoedema Support Network; British Lymphology Society. Consensus document on the management of cellulitis in lymphoedema; December 2016. https://www.lymphoedema.org/images/pdf/CellulitisConsensus.pdf. Accessed 6 Aug 2018.
Kwak YG, Choi SH, Kim T, Park SY, Seo SH, Kim MB, et al. Clinical guidelines for the antibiotic treatment for community-acquired skin and soft tissue infection. Infect Chemother. 2017;49:301–25. https://doi.org/10.3947/ic.2017.49.4.301.
Obaitan I, Dwyer R, Lipworth AD, Kupper TS, Camargo CA Jr, Hooper DC, et al. Failure of antibiotics in cellulitis trials: a systematic review and meta-analysis. Am J Emerg Med. 2016;34:1645–52. https://doi.org/10.1016/j.ajem.2016.05.064.
U.S. Department of Health and Human Services Food and Drug Administration; Center for Drug Evaluation and Research (CDER). Acute bacterial skin and skin structure infections: developing drugs for treatment. http://www.fda.gov/downloads/Drugs/…/Guidances/ucm071185.pdf. Accessed 6 Aug 2018.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097. https://doi.org/10.1371/journal.pmed.
Wise R. The pharmacokinetics of the oral cephalosporins—a review. J Antimicrob Chemother. 1990;26 Suppl E:13–20.
Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
Wells GA, Shea B, O’Connel D, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm. Accessed 14 Aug 2018.
Yadav K, Gatien M, Corrales-Medina V, Stiell I. Antimicrobial treatment decision for non-purulent skin and soft tissue infections in the emergency department. CJEM. 2017;19:175–80. https://doi.org/10.1017/cem.2016.347.
Smith E, Patel M, Thomas KS. Which outcomes are reported in cellulitis trials? Results of a review of outcomes included in cellulitis trials and a patient priority setting survey. Br J Dermatol. 2018;178:1028–34.
Kilburn SA, Featherstone P, Higgins B, Brindle R. Interventions for cellulitis and erysipelas. Cochrane Database Syst Rev. 2010;6:004299. https://doi.org/10.1002/14651858.cd004299.pub2.
Williamson PR, Altman DG, Bagley H, Barnes KL, Blazeby JM, Brookes ST, et al. The COMET handbook: version 1.0. Trials. 2017;18:280.
McCormack HM, Horne DJ, Sheather S. Clinical applications of visual analogue scales: a critical review. Psychol Med. 1988;18:1007–19.
Childs JD, Piva SR, Fritz JM. Responsiveness of the numeric pain rating scale in patients with low back pain. Spine. 2005;30:1331–4.
Conway EL, Sellick JA, Kurtzhalts K, Mergenhagen KA. Obesity and heart failure as predictors of failure in outpatient skin and soft tissue infections. Antimicrob Agents Chemother. 2017;61:e02389–16.
Kaufman KR, Thurber KM, O’Meara JG, Langworthy DR, Kashiwagi DT. Evaluation of cephalexin failure rates in morbidly obese patients with cellulitis. J Clin Pharm Ther. 2016;41:409–13.
Kiani R. Double-blind, double-dummy comparison of azithromycin and cephalexin in the treatment of skin and skin structure infections. Eur J Clin Microbiol Infect Dis. 1991;10:880–4.
Madaras-Kelly KJ, Remington RE, Oliphant CM, Sloan KL, Bearden DT. Efficacy of oral beta-lactam versus non-beta-lactam treatment of uncomplicated cellulitis. Am J Med. 2008;121:419–25.
Madaras-Kelly KJ, Arbogast R, Jue S. Increased therapeutic failure for cephalexin versus comparator antibiotics in the treatment of uncomplicated outpatient cellulitis. Pharmacotherapy. 2000;20:199–205.
Moran GJ, Krishnadasan A, Mower WR, Abrahamian FM, LoVecchio F, Steele MT, et al. Effect of cephalexin plus trimethoprim-sulfamethoxazole vs cephalexin alone on clinical cure of uncomplicated cellulitis: a randomized clinical trial. JAMA. 2017;317:2088–96.
Theofiles M, Maxson J, Herges L, Marcelin A, Angstman KB. Cellulitis in obesity: adverse outcomes affected by increases in body mass index. J Prim Care Community Health. 2015;6:233–8.
Wells RD, Mason P, Roarty J, Dooley M. Comparison of initial antibiotic choice and treatment of cellulitis in the pre- and post-community-acquired methicillin-resistant Staphylococcus aureus eras. Am J Emerg Med. 2009;27:436–9.
Bader MS, Twells L, Hawboldt J. Risk factors of cellulitis treatment failure with once-daily intravenous cefazolin plus oral probenecid. South Med J. 2011;104:789–93.
Chan JC. Ampicillin/sulbactam versus cefazolin or cefoxitin in the treatment of skin and skin-structure infections of bacterial etiology. Adv Ther. 1995;12:139–46.
Gentry LO. Treatment of skin, skin structure, bone, and joint infections with ceftazidime. Am J Med. 1985;79:67–74.
Grayson ML, McDonald M, Gibson K, Athan E, Munckhof WJ, Paull P, et al. Once-daily intravenous cefazolin plus oral probenecid is equivalent to once-daily intravenous ceftriaxone plus oral placebo for the treatment of moderate-to-severe cellulitis in adults. Clin Infect Dis. 2002;34:1440–8.
Housman E, Livings SE, Knee A, Schimmel J. Improving management of hospitalized adults with uncomplicated cellulitis or cutaneous abscess. Open Forum Infect Dis. 2017;4:ofx094.
Leder K, Turnidge JD, Grayson ML. Home-based treatment of cellulitis with twice-daily cefazolin. Med J Aust. 1998;169:519–22.
Tan JS, File TM, Salstrom SJ. Timentin versus moxalactam in the treatment of skin and soft tissue infections. Am J Med. 1985;79:130–3.
Yadav K, Suh KN, Eagles D, Thiruganasambandamoorthy V, Wells GA, Stiell IG. Evaluation of an emergency department to outpatient parenteral antibiotic therapy program for cellulitis. Am J Emerg Med. 2019. https://doi.org/10.1016/j.ajem.2019.02.023.
Zhang J, Moore E, Bousfield R. OPAT for cellulitis: its benefits and the factors that predispose to longer treatment. Eur J Clin Microbiol Infect Dis. 2016;35:1013–5. https://doi.org/10.1007/s10096-016-2631-y.
Aboltins CA, Hutchinson AF, Sinnappu RN, Cresp D, Risteski C, Kathirgamanathan R, et al. Oral versus parenteral antimicrobials for the treatment of cellulitis: a randomized non-inferiority trial. J Antimicrob Chemother. 2015;70:581–6. https://doi.org/10.1093/jac/dku397.
Cieri B, Conway EL, Sellick JA, Mergenhagen KA. Identification of risk factors for failure in patients with skin and soft tissue infections. Am J Emerg Med. 2019;37:48–52.
Dalen D, Fry A, Campbell SG, Eppler J, Zed PJ. Intravenous cefazolin plus oral probenecid versus oral cephalexin for the treatment of skin and soft tissue infections: a double-blind, non-inferiority, randomised controlled trial. Emerg Med J. 2018;35:492–8. https://doi.org/10.1136/emermed-2017-207420.
Hepburn MJ, Dooley DP, Skidmore PJ, Ellis MW, Starnes WF, Hasewinkle WC. Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med. 2004;164:1669–74.
Jenkins TC, Knepper BC, Sabel AL, Sarcone EE, Long JA, Haukoos JS, et al. Decreased antibiotic utilization after implementation of a guideline for inpatient cellulitis and cutaneous abscess. Arch Intern Med. 2011;171:1072–9.
Jenkins TC, Sabel AL, Sarcone EE, Price CS, Mehler PS, Burman WJ. Skin and soft-tissue infections requiring hospitalization at an academic medical center: opportunities for antimicrobial stewardship. Clin Infect Dis. 2010;51:895–903.
Murray H, Stiell I, Wells G. Treatment failure in emergency department patients with cellulitis. CJEM. 2005;7:228–34.
Peterson D, McLeod S, Woolfrey K, McRae A. Predictors of failure of empiric outpatient antibiotic therapy in emergency department patients with uncomplicated cellulitis. Acad Emerg Med. 2014;21:526–31.
Acknowledgements
The authors would like to thank Natalie LeClair for providing peer review of the electronic search strategy.
Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Yadav, K., Nath, A., Suh, K.N. et al. Treatment failure definitions for non-purulent skin and soft tissue infections: a systematic review. Infection 48, 75–83 (2020). https://doi.org/10.1007/s15010-019-01347-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15010-019-01347-w